Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in papillary tip epithelial cells | 0.75 |
| chemistry Open Targets | reachable by antibody: pf-06263507, anatumomab mafenatox, naptumomab estafenatox | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 55 | 0.82 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3249
Sealed predictions
- TPBG in dopamine neurons, braak+0.09 (p 0.825) → +0.01 (p 0.982)receipt 3256
Swarm cases
receipt 3256: TPBG in dopamine neurons, braak
- power
- full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.847, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.976, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.14, sign flips 7; without severely affected donors -0.01 (p 0.969, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TPBG in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts